GlassScriptPhysician profile
Jamie Lee Durchin
NPI 1649354812
$69,329.81
in general payments reported to CMS, 2019-2025
36 companies · $6,513 in 2025
The $6,513 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $12K · 2023: $24K · 2024: $15K · 2025: $6,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $10K · Travel and Lodging: $2,787 · Education: $24.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,734.75 |
| Food and Beverage | $10,148.59 |
| Travel and Lodging | $2,786.87 |
| Education | $24.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,314.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $19,102.12 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,473.43 | 2021-2025 | Caplyta |
| Alkermes, INC. | $1,224.30 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $872.35 | 2021-2025 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $766.62 | 2021-2025 | Trintellix |
| Lundbeck LLC | $644.34 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $616.36 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $549.14 | 2022-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $463.04 | 2021-2025 | Ingrezza |
| Tris Pharma INC | $461.28 | 2022-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Noven Therapeutics, LLC | $446.82 | 2023-2025 | Xelstrym, Secuado |
| Teva Pharmaceuticals USA, INC. | $320.90 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Validus Pharmaceuticals LLC | $305.19 | 2023-2025 | Equetro, Equetro, Raldesy |
| Janssen Pharmaceuticals, INC | $299.96 | 2022-2025 | Spravato, Invega Sustenna, Invega |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $265.41 | 2022-2025 | Gralise, Loreev Xr |
| Bausch Health US, LLC | $249.00 | 2021-2025 | Wellbutrin, Aplenzin |
| E.R. Squibb & Sons, L.L.C. | $230.65 | 2024-2025 | Cobenfy |
| Neos Therapeutics, LP | $229.90 | 2021-2024 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $178.94 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $164.18 | 2022-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $148.45 | 2022-2024 | Jornay Pm |
| Tempus Ai, INC | $141.88 | 2024 | |
| Vanda Pharmaceuticals INC. | $138.72 | 2021-2024 | Fanapt, Hetlioz |
| Indivior INC. | $127.42 | 2021-2024 | Sublocade |
| Biogen, INC. | $125.02 | 2023 | |
| Eisai INC. | $115.46 | 2021-2022 | |
| Blue Earth Diagnostics | $93.24 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $90.12 | 2021 | |
| Merck Sharp & Dohme LLC | $34.70 | 2022 | |
| Adlon Therapeutics L.P. | $32.65 | 2021 | |
| Braeburn INC. | $27.57 | 2025 | Brixadi |
| Neuronetics, INC. | $27.28 | 2023 | Neurostar Tms Therapy System |
| Amgen INC. | $20.04 | 2022 | |
| Vertical Pharmaceuticals, LLC | $15.11 | 2025 | Relexxii |
| Acadia Pharmaceuticals INC | $14.15 | 2023 | Nuplazid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Durchin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.